Last reviewed · How we verify

NCT06711822

The Safety and Performence of ShockPulse-10 in Patients with Coronary Artery Calcification

Recruiting now NA Last updated 2 December 2024
What this trial tests

NA trial testing Shockplus-10 in Coronary Arterial Disease (CAD) in 205 participants. Currently enrolling.

Timeline
1 July 2024
Primary endpoint
30 June 2025
30 December 2025

Quick facts

Lead sponsorKeya Medical
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment205
Start date1 July 2024
Primary completion30 June 2025
Estimated completion30 December 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Keya Medical

Who can join

18 and older, any sex, with Coronary Arterial Disease (CAD) or Calcification; Heart. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an exploratory, multicenter, single-group clinical trial aimed to evaluate the clinical outcomes of using ShockPulse-10 in the treatment of coronary artery calcification .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Arterial Disease (CAD)

Currently open trials in the same condition.

Other Keya Medical trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06711822.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing